[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

EA200702169A1 - Профилактика вич-инфекции - Google Patents

Профилактика вич-инфекции

Info

Publication number
EA200702169A1
EA200702169A1 EA200702169A EA200702169A EA200702169A1 EA 200702169 A1 EA200702169 A1 EA 200702169A1 EA 200702169 A EA200702169 A EA 200702169A EA 200702169 A EA200702169 A EA 200702169A EA 200702169 A1 EA200702169 A1 EA 200702169A1
Authority
EA
Eurasian Patent Office
Prior art keywords
hiv prevention
hiv infection
composition
long
hiv
Prior art date
Application number
EA200702169A
Other languages
English (en)
Other versions
EA011420B1 (ru
Inventor
Ливен Элвире Колетт Барт
Паулюс Йоханнес Леви
Ян Херес
Original Assignee
Тиботек Фармасьютикалз Лтд.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Тиботек Фармасьютикалз Лтд. filed Critical Тиботек Фармасьютикалз Лтд.
Publication of EA200702169A1 publication Critical patent/EA200702169A1/ru
Publication of EA011420B1 publication Critical patent/EA011420B1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Dermatology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • AIDS & HIV (AREA)
  • Molecular Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

Это изобретение относится к применению парентеральной композиции, включающей NNRTI TMC278 для длительной профилактики ВИЧ-инфекции у субъекта, имеющего риск инфицирования ВИЧ, которое включает периодическое введение упомянутой композиции через длительные интервалы времени.
EA200702169A 2005-04-04 2006-04-04 Профилактика вич-инфекции EA011420B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP05102616 2005-04-04
PCT/EP2006/061303 WO2006106103A2 (en) 2005-04-04 2006-04-04 Prevention of hiv- infection with tmc278

Publications (2)

Publication Number Publication Date
EA200702169A1 true EA200702169A1 (ru) 2008-02-28
EA011420B1 EA011420B1 (ru) 2009-02-27

Family

ID=34939113

Family Applications (1)

Application Number Title Priority Date Filing Date
EA200702169A EA011420B1 (ru) 2005-04-04 2006-04-04 Профилактика вич-инфекции

Country Status (29)

Country Link
US (6) US20080194601A1 (ru)
EP (1) EP1881848B1 (ru)
JP (2) JP5632579B2 (ru)
KR (1) KR101360851B1 (ru)
CN (2) CN101155599A (ru)
AP (1) AP2617A (ru)
AR (1) AR053571A1 (ru)
AU (1) AU2006231585B2 (ru)
BR (1) BRPI0607649B8 (ru)
CA (1) CA2602231C (ru)
CY (1) CY1113950T1 (ru)
DK (1) DK1881848T3 (ru)
EA (1) EA011420B1 (ru)
ES (1) ES2402864T3 (ru)
HK (2) HK1117039A1 (ru)
HR (1) HRP20130296T1 (ru)
IL (1) IL184744A (ru)
ME (1) ME01517B (ru)
MX (1) MX2007012277A (ru)
MY (1) MY150091A (ru)
NZ (1) NZ556659A (ru)
PL (1) PL1881848T3 (ru)
PT (1) PT1881848E (ru)
RS (1) RS52724B (ru)
SI (1) SI1881848T1 (ru)
TW (2) TW201414495A (ru)
UA (1) UA90124C2 (ru)
WO (1) WO2006106103A2 (ru)
ZA (1) ZA200708454B (ru)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY169670A (en) 2003-09-03 2019-05-08 Tibotec Pharm Ltd Combinations of a pyrimidine containing nnrti with rt inhibitors
TW201414495A (zh) * 2005-04-04 2014-04-16 Tibotec Pharm Ltd Ｈｉｖ-感染之預防
SI1981506T1 (sl) 2006-01-20 2013-08-30 Janssen R&D Ireland Dolgoročno zdravljenje infekcije HIV s TCM278
TWI413521B (zh) * 2006-06-23 2013-11-01 Tibotec Pharm Ltd Ｔｍｃ２７８之水性懸浮液
AR065720A1 (es) 2007-03-14 2009-06-24 Tibotec Pharm Ltd Polvos para reconstitucion que comprenden rilpivirina dispersos en ciertos polimeros. uso. proceso.
WO2010072844A1 (en) * 2008-12-24 2010-07-01 Tibotec Pharmaceuticals Implantable devices for treating hiv
US8784858B2 (en) 2009-12-21 2014-07-22 Janssen R&D Ireland Degradable removable implant for the sustained release of an active compound
DE102011082871A1 (de) * 2011-09-16 2013-03-21 Florian, Prof. Dr. Lang Therapeutische und diagnostische Targets für Autoimmunität, inflammatorische Prozesse und/oder immuner Pathogenese und/oder von Erkrankungen, welche auf Autoimmunität, inflammatorische Prozessen und/oder immuner Pathogenese beruhen
JO3387B1 (ar) 2011-12-16 2019-03-13 Glaxosmithkline Llc مشتقات بيتولين
CN104902905A (zh) 2012-12-14 2015-09-09 葛兰素史克有限责任公司 药物组合物
CR20170113A (es) * 2014-09-26 2017-05-26 Glaxosmilthkline Intellectual Property (No 2) Ltd Composiciones farmacéuticas de acción prolongada
WO2022079739A1 (en) 2020-10-14 2022-04-21 Cipla Limited Fixed dose compositions of cabotegravir and rilpivirine
KR20240170635A (ko) 2023-05-24 2024-12-04 서울대학교산학협력단 R-루프의 생성을 저해시켜 hiv 감염을 억제하는 방법 및 이의 용도

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH06316524A (ja) 1992-09-11 1994-11-15 Naoyuki Inoue 抗エイズウイルス剤
US6258932B1 (en) 1999-08-09 2001-07-10 Tripep Ab Peptides that block viral infectivity and methods of use thereof
US7135465B2 (en) 2000-03-30 2006-11-14 Bristol-Myers Squibb Company Sustained release beadlets containing stavudine
US20040115268A1 (en) * 2000-04-26 2004-06-17 Control Delivery Systems, Inc. Systemic delivery of antiviral agents
JO3429B1 (ar) 2001-08-13 2019-10-20 Janssen Pharmaceutica Nv مشتقات برميدينات مثبطة فيروس الايدز
MY169670A (en) * 2003-09-03 2019-05-08 Tibotec Pharm Ltd Combinations of a pyrimidine containing nnrti with rt inhibitors
JP2006508134A (ja) 2002-11-08 2006-03-09 グラクソ　グループ　リミテッド 医薬組成物
US7204980B2 (en) 2002-11-18 2007-04-17 Phoenix Pharmacologics, Inc. Methods for inhibiting viral replication in vivo
EA011164B1 (ru) 2003-02-07 2009-02-27 Янссен Фармацевтика Н. В. Производные пиримидина для профилактики вич-инфекции
PL378163A1 (pl) 2003-02-21 2006-03-06 Tripep Ab Pochodna glicynoamidu do hamowania replikacji HIV
TW201414495A (zh) * 2005-04-04 2014-04-16 Tibotec Pharm Ltd Ｈｉｖ-感染之預防
SI1981506T1 (sl) * 2006-01-20 2013-08-30 Janssen R&D Ireland Dolgoročno zdravljenje infekcije HIV s TCM278
TWI413521B (zh) * 2006-06-23 2013-11-01 Tibotec Pharm Ltd Ｔｍｃ２７８之水性懸浮液

Also Published As

Publication number Publication date
MY150091A (en) 2013-11-29
BRPI0607649A2 (pt) 2009-09-22
CA2602231A1 (en) 2006-10-12
PL1881848T3 (pl) 2013-06-28
CA2602231C (en) 2014-03-25
IL184744A0 (en) 2007-12-03
NZ556659A (en) 2012-03-30
JP2013079275A (ja) 2013-05-02
US20110077261A1 (en) 2011-03-31
EA011420B1 (ru) 2009-02-27
SI1881848T1 (sl) 2013-05-31
US20080194601A1 (en) 2008-08-14
BRPI0607649B8 (pt) 2021-05-25
US10765674B2 (en) 2020-09-08
HK1198936A1 (en) 2015-06-19
AP2007004178A0 (en) 2007-10-31
AU2006231585B2 (en) 2012-02-02
AP2617A (en) 2013-03-18
HRP20130296T1 (hr) 2013-04-30
EP1881848B1 (en) 2013-01-16
TWI457136B (zh) 2014-10-21
UA90124C2 (ru) 2010-04-12
MX2007012277A (es) 2007-10-17
ES2402864T3 (es) 2013-05-09
CN103860560A (zh) 2014-06-18
RS52724B (en) 2013-08-30
ME01517B (me) 2014-04-20
IL184744A (en) 2015-05-31
US20220071997A1 (en) 2022-03-10
JP5632579B2 (ja) 2014-11-26
PT1881848E (pt) 2013-04-15
BRPI0607649B1 (pt) 2019-08-06
EP1881848A2 (en) 2008-01-30
KR101360851B1 (ko) 2014-02-11
TW201414495A (zh) 2014-04-16
AR053571A1 (es) 2007-05-09
CN101155599A (zh) 2008-04-02
DK1881848T3 (da) 2013-04-15
KR20080009051A (ko) 2008-01-24
CY1113950T1 (el) 2016-07-27
ZA200708454B (en) 2009-03-25
JP2008534651A (ja) 2008-08-28
WO2006106103A2 (en) 2006-10-12
AU2006231585A1 (en) 2006-10-12
WO2006106103A3 (en) 2007-06-07
US20200397783A1 (en) 2020-12-24
HK1117039A1 (en) 2009-01-09
US20160296519A1 (en) 2016-10-13
TW200709818A (en) 2007-03-16
US20160151276A1 (en) 2016-06-02

Similar Documents

Publication Publication Date Title
EA200702169A1 (ru) Профилактика вич-инфекции
MX2010004576A (es) Derivados de pirimidina novedosos.
EA200702529A1 (ru) Фунгицидная комбинация биологически активных веществ
DK2110104T3 (da) Skinne med digital dorsalfleksion til natbrug
DK2004641T3 (da) HIV-inhiberende 5-(hydroxymethylen og aminomethylen) substituerede pyrimidiner
EA200401494A1 (ru) Бактерицидные пиримидины или триазины для профилактики передачи вич половым путём
EA201200631A1 (ru) Ингибиторы репликации вируса иммунодефицита человека
UA112428C2 (uk) Пестицидні композиції і пов'язані з ними способи
TW200626559A (en) Anilino-pyrimidine analogs
CY1114089T1 (el) Μακροχρονια θεραπεια της μολυνσης απο hiv με tcm278
TW200800968A (en) Sulfoximine-substituted pyrimidines, processes for production thereof and use thereof as drugs
EA201070786A1 (ru) Бензофуропиримидиноны
CY1115852T1 (el) Φαρμακευτικες συνθεσεις
CL2007000595A1 (es) Compuestos derivados de piperidina; composicion farmaceutica y uso para el tratamiento y/o profilaxis de enfermedades seleccionadas entre hipertension, insuficiencia cardiaca congestiva e insuficiencia renal entre otras.
MX2009009952A (es) Sal clorhidrato de 5-[3-(3-hidroxifenoxi)azetidin-1-il]-5-metil-2, 2-difenilhexanamida.
MA35816B1 (fr) Dérivés d'aniline, leur préparation et leur application thérapeutique
EA201490761A1 (ru) R(+)-n-формилпропаргиламиноиндан
MX2007010143A (es) Formas cristalinas de intermedio de linezolid.
ES2531159T3 (es) Compuestos y métodos para el tratamiento del cáncer
MA32834B1 (fr) 3-aminocyclopentanecarboxamides servant de modulateurs de recepteurs de chimiokines
EA201590790A1 (ru) СТАБИЛЬНАЯ ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ НА ОСНОВЕ PEG-ИНТЕРФЕРОНА АЛЬФА-2b
BR112014030755A2 (pt) composições de intensificação de culturas
MX2010001303A (es) Compuestos terapeuticos.
EP2183256A4 (en) THERAPEUTIC COMPOUNDS
DE602008002598D1 (en) Cyclohexylderivate

Legal Events

Date Code Title Description
PC4A Registration of transfer of a eurasian patent by assignment
TC4A Change in name of a patent proprietor in a eurasian patent